August 21, 2024
Frankfurt am Main, August 21, 2024. Hesse's Economics Minister Kaweh Mansoori (SPD) and the Mayor of Offenbach, Dr. Felix Schwenke (SPD), visited BioSpring GmbH in Frankfurt, Germany, to learn more about the production of innovative active ingredients for future medicines and how this advancement continues to drive the company's economic growth.
The discussions at BioSpring's Frankfurt headquarters focused specifically on future technologies such as the production of innovative, highly effective nucleic acid-based active pharmaceutical ingredients, and the added value that can be generated from such special biotechnology applications.
“We are delighted to be able to continue the dialogue with politicians through the visit of Minister Mansoori and Mayor Schwenke,” said Dr. Sylvia Wojczewski, Chief Executive Officer (CEO) and co-owner of BioSpring. “We want to continue to invest and grow, thereby contributing to economic development in Hesse. With our commitment, we are creating new and attractive jobs in the Rhine-Main region.“
Minister Mansoori and Mayor Schwenke visited BioSpring's clean room production facilities and quality control laboratories in Frankfurt Fechenheim. Minister Mansoori praised BioSpring's positive impact on the state's economy: “I am delighted that BioSpring is successfully manufacturing active pharmaceutical ingredients in Hesse. Here in Fechenheim, BioSpring is an impressive example of innovation. It is a clear signal of the key role that medical biotechnology plays as an industry of the future in Hesse.” Mayor Schwenke commented, “A lot has happened at BioSpring since my last visit. The company is growing and has continuously created new jobs in the region as planned. We strongly support the company's plans to build new production facilities on the innovation campus in Offenbach. This will turn the city into a biotechnology location of international standing. As communicated from the outset, not overnight, but step by step and with a long-term perspective. For us, this is an important building block in further strengthening Offenbach as a business location overall and making it fit for the future.”
BioSpring is one of the world's leading manufacturers of synthetic nucleic acids and partnering with renowned multinational biotech and pharmaceutical companies. BioSpring is the global market leader in the production of molecules used in genome editing. Genome editing specifically corrects genetic defects and therefore has the potential to completely cure genetic diseases with just one treatment - in contrast to conventional therapies, which only combat the symptoms.
BioSpring manufactures exclusively in Germany and has created hundreds of new jobs in the recent years. The company intends to expand further in the coming years and is currently planning the construction of new production facilities on an industrial scale in Offenbach am Main, Germany. In the long term, up to 1,500 jobs are to be created there.
